One-third of people over the age of 65 wait longer than necessary for lifesaving, new kidneys because their doctors fail to put them in a queue for organs unsuitable to transplant in younger patients but well-suited to seniors, research from Johns Hopkins suggests. Results of a study reported online in the American Journal of Transplantation show that older patients could be receiving kidneys from older donors (called extended-criteria donors, or ECDs), but instead are unnecessarily waiting longer for kidneys from younger donors. "Every adult over 65 should be listed by their physicians for ECDs because the sooner they can get a kidney, the better the chance for survival, " says transplant surgeon Dorry L.
A novel - and rapid - anti-cancer drug development strategy has resulted in a new drug that stops kidney and pancreatic tumors from growing in mice. Researchers at the Moores Cancer Center at the University of California, San Diego, have found a drug that binds to a molecular "switch" found in cancer cells and cancer-associated blood vessels to keep it in the "off" position. "We locked the kinase switch in the off position in cancer and in tumor-associated blood vessels, " which differs from the way current inhibitors attempt to block active kinases, said David Cheresh, PhD, professor and vice chair of pathology at the UCSD School of Medicine and the Moores UCSD Cancer Center, who led the work.
NEPHROLOGY: New approach to treating the kidney disease Alport syndrome? Alport syndrome is a progressive hereditary kidney disease with no definitive therapy. It is caused by mutations in any of the collagen IV genes (COL4A3, COL4A4, and COL4A5). Motoko Yanagita and colleagues, at Kyoto University Graduate School of Medicine, Japan, have now identified a role for the protein USAG-1 in the development of disease in mice that model Alport syndrome (Col4a3-/- mice). As deletion of Usag1 in Col4a3-/- mice led to substantial attenuation of disease progression, preservation of kidney function, and extension of life span, the authors suggest that inhibiting USAG-1 might be a promising therapeutic approach for the treatment of Alport syndrome.
Repros Submits Response To FDA Regarding Androxal R Indication For Treatment Of Hypogonadal Men Wishing To Preserve Fertility
Repros Therapeutics Inc. (NasdaqCM:RPRX) announced that the Company, as requested by the FDA during the Type C meeting held on January 25, 2010, has sent a revised indication statement to the FDA's Division of Reproductive and Urologic Products for the use of Androxal® in the treatment of men wishing to preserve fertility while being treated for their hypogonadal state. The Company also provided a literature review supporting the Company's belief that administration of exogenous testosterone at doses resulting in morning testosterone levels within the normal range render a significant number of men oligospermic (sperm counts less than the generally accepted level of male fertility).
Pelvic health concerns in women are common -- yet how the issues impact sexuality and childbearing is not often discussed, according to Mayo Clinic Women's HealthSource. The February issue features an overview of pelvic health problems, risk factors, causes and treatment options. The key recommendation is that women should talk to their doctors about pelvic health concerns because several treatment options, including physical therapy, can help. The pelvic floor holds in place the uterus, bladder and rectum. Over time, the pelvic floor may stretch, weaken or become excessively tense. The tension or loss of support can lead to pain, bladder and bowel problems, pain during sexual intercourse and other symptoms.
In patients with type 2 diabetes, silent cerebral infarction (SCI) small areas of brain damage caused by injury to small blood vessels signals an increased risk of progressive kidney disease and kidney failure, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). If SCI is present in the brain, it could be an indicator that small-vessel damage is present in the kidneys as well, suggests the new study by Takashi Uzu, MD (Shiga University School of Medicine, Otsu, Japan). Uzu comments, "Silent cerebral infarction may be a new marker to identify patients who are risk for declining kidney function.